ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,815.03
0.61%
US Tech 100
19,717.60
0.07%
Dow Jones
42,863.86
0.97%
Brent Oil
78.695
-0.46%
Bitcoin
62,974.91
4.48%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Caribou Biosciences Inc (CRBU) Quote

Caribou Biosciences Inc

Caribou Biosciences Inc (CRBU)

Amd Commo Exagr
1.90
0.10
(5.56%)
At close: October 11 4:00PM
Delayed by 15 minutes
1.90
0.00
( 0.00% )
After Hours: 4:47PM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
1.90
Bid
1.81
Ask
1.90
Volume
953,084
1.77 Day's Range 1.90
1.50 52 Week Range 8.33
Market Cap
171.689M
Previous Close
1.80
Open
1.80
Last Trade
3
@
1.81
Last Trade Time
16:31:30
Financial Volume
$ 1,773,424
VWAP
1.8607
Average Volume (3m)
966,286
Shares Outstanding
90,362,771
Dividend Yield
-
PE Ratio
-1.68
Earnings Per Share (EPS)
-1.13
Revenue
34.48M
Net Profit
-102.07M

About Caribou Biosciences Inc

Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.cariboubio.com
Headquarters
Dover, Delaware, USA
Founded
-
Caribou Biosciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CRBU. The last closing price for Caribou Biosciences was $1.80. Over the last year, Caribou Biosciences shares have traded in a share price range of $ 1.50 to $ 8.33.

Caribou Biosciences currently has 90,362,771 shares outstanding. The market capitalization of Caribou Biosciences is $162.65 million. Caribou Biosciences has a price to earnings ratio (PE ratio) of -1.68.

Ask ADVFN Intelligence (AI)

CRBU Latest News

More News

Form 3 - Initial statement of beneficial ownership of securities

October 04 2024
Edgar (US Regulatory)

Form 8-K/A - Current report: [Amend]

September 27 2024
Edgar (US Regulatory)

Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024

BERKELEY, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an...

September 25 2024
GlobeNewswire Inc.

Form 8-K - Current report

September 03 2024
Edgar (US Regulatory)

Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML

-- Fast Track designation is designed to expedite clinical development and regulatory review timelines -- -- Additional FDA designation for CB-010 following earlier RMAT and Fast Track...

September 03 2024
GlobeNewswire Inc.

Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced company...

August 26 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

August 20 2024
Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities

August 20 2024
Edgar (US Regulatory)

Form 8-K - Current report

August 12 2024
Edgar (US Regulatory)

Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer

-- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies -- BERKELEY, Calif., Aug. 12, 2024 (GLOBE...

August 12 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.052.70270270271.851.9451.786951761.85406892CS
4-0.19-9.090909090912.092.2251.748124481.93978972CS
12-0.455-19.32059447982.3552.5751.639662862.04415087CS
26-2.52-57.01357466064.424.421.517780692.46274422CS
52-2.64-58.14977973574.548.331.517207243.90334622CS
156-17.31-90.109318063519.21241.512300705.86872238CS
260-15.75-89.235127478817.6532.6451.512116736.81125182CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TVGNTevogen Bio Holdings Inc
$ 1.02
(168.70%)
21.08M
XPONExpion360 Inc
$ 2.97
(24.27%)
886.31k
CELUCelularity Inc
$ 3.03
(20.72%)
621
PETZTDH Holdings Inc
$ 1.40
(12.00%)
2k
MDIAMediaco Holding Inc
$ 1.29
(11.21%)
15.63k
ZPTAZapata Computing Holdings Inc
$ 0.0948
(-63.68%)
1M
TWGTop Wealth Group Holding Ltd
$ 5.40
(-24.37%)
3.71M
DWTXDogwood Therapeutics Inc
$ 3.32
(-19.42%)
30.2k
MTEMMolecular Templates Inc
$ 1.21
(-17.69%)
10.87k
IBGInnovation Beverage Group Limited
$ 0.8598
(-14.02%)
162.85k
TVGNTevogen Bio Holdings Inc
$ 1.02
(168.70%)
21.08M
JTAIJet AI Inc
$ 0.094
(-6.93%)
5.28M
TWGTop Wealth Group Holding Ltd
$ 5.40
(-24.37%)
3.71M
NVDANVIDIA Corporation
$ 134.57
(-0.17%)
2.26M
CDTConduit Pharmaceuticals Inc
$ 0.1077
(-7.47%)
1.92M

CRBU Discussion

View Posts
Monksdream Monksdream 5 days ago
CRBU under $2
👍️0
Monksdream Monksdream 1 month ago
CRBU under $3
👍️0
Monksdream Monksdream 3 months ago
CRBU under $3
👍️0
jondoeuk jondoeuk 3 months ago
Earlier this year development of the lead CAR-NK programme, CB-020, was stopped, and now they are out of CAR-NK altogether. They disclosed it in an SEC filing and outlined a 12% workforce reduction https://www.sec.gov/Archives/edgar/data/1619856/000161985624000054/crbu-20240716.htm

This should extend their cash runway by at least six months, into the second half of 2026.
👍️0
Monksdream Monksdream 3 months ago
CRBU under $3
👍️0
Monksdream Monksdream 3 months ago
CRBU new 52 week low
👍️0
Monksdream Monksdream 4 months ago
CRBU new 52 week low
👍️0
NY1972 NY1972 4 months ago
Without engaging macrophage long term, CART and other ACT will have persistence issue as regulatory lymphocytes and TAM recoup. AFMD has the best approach with ICE engaging a few B CBNK cells for start and engaging endogenous NK and M in the maintenance phase
👍️0
Diego Rivas Diego Rivas 4 months ago
Any good news in here comming?
👍️0
jondoeuk jondoeuk 4 months ago
Among patients with four or more matching HLA alleles, mPFS was 14.4 months, versus 2.8 months in patients with three or fewer matches. But this is based on a retrospective analysis, so they will need to prove the theory prospectively. It was better in LBCL, with mPFS not reached, versus 2.8 months. Also, some improvement in the now-selected dose, 80 million CAR-T cells.
👍️0
jondoeuk jondoeuk 4 months ago
The BCMA-targeted space is already crowded enough and off-target toxicities, including agranulocytosis* could be a problem for its anti-CLL-1 CAR.

* CLL-1 is also highly expressed on almost all granulocytes and monocytes and on parts of myeloid progenitors in the normal bone marrow and peripheral blood.
👍️0
Monksdream Monksdream 4 months ago
CRBU new 52 week low
👍️0
stocksrising stocksrising 4 months ago
Yep, not a positive trend hence sub $3’s…fortunately other trials for varied indications could save company…
👍️0
jondoeuk jondoeuk 4 months ago
It gets worse. The updated (CB-010) data shows that the ORR (including CR rate) has fallen, so has the mDOR, the six-month PFS is poor and the pivotal trial has been delayed until H2 2025 following a new HLA partial matching strategy. The latter completely alters (in a bad way) the commercial strategy for an allo CAR-T product. They now need thirteen different off-the-shelf batches to be able to cater to ~90% of patients based on an ideal HLA match.
👍️ 1
Monksdream Monksdream 5 months ago
CRBU new 52 week low
👍️0
Monksdream Monksdream 5 months ago
CRBU new 52 week low
👍️0
Monksdream Monksdream 5 months ago
CRBU under $5
👍️0
stocksrising stocksrising 7 months ago
It seemed like they were running on all positive cylinders, but must have blown a gasket at current Conference/ Fireside???
👍️0
Monksdream Monksdream 12 months ago
CRBU new 52 week low
👍️0
jondoeuk jondoeuk 1 year ago
Yes, with both drugs still in development. As for CRBU, they gave an update (plus public offering) https://finance.yahoo.com/news/caribou-biosciences-reports-positive-clinical-200100822.html https://investor.cariboubio.com/static-files/d818ed1a-aea2-41c1-84ea-bd05a4276cbb

Personally, there seem to be red flags, such as no expansion/persistence data. I know they give huge amounts of LD chemo, higher (I think) than anyone else, which could be generating responses, explaining why there is no dose response.
👍️0
trueblue trueblue 1 year ago
.
👍️0
trueblue trueblue 1 year ago
$23.00 price target! Now that is a good start!! Glad I loaded up! Jmo
👍️0
NY1972 NY1972 1 year ago
Didn't they buy TRIL? Just gambling with billions from US government.
👍️0
jondoeuk jondoeuk 1 year ago
PFE is very selective in who they fund https://finance.yahoo.com/news/caribou-biosciences-announces-25-million-120000433.html
👍️0
trueblue trueblue 1 year ago
Great day in my accounts again! Really liking my CRBU shares! Jmo holding for the long haul!!
👍️0
Monksdream Monksdream 1 year ago
CRBU now No 9 on the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
trueblue trueblue 1 year ago
Added to my existing shares today, I bought shares months ago. I like Crbu a crisper company! Looks like Pfizer does also! Jmo
👍️0
Stockexpertpro Stockexpertpro 1 year ago
CRBU Loss 108 Million Dollars Company only has preclinical and phase 1 in its pipeline company is Years away from having anything if ever did a stock offering at 5.33$ for 25 Million thats only 1 QTR Cash burn for this company Sell the News https://www.cariboubio.com/pipeline/
👍️0
TheFinalCD TheFinalCD 1 year ago
CRBU= JUST WOW

https://finviz.com/quote.ashx?t=CRBU&ty=c&ta=1&p=d
👍️0
Monksdream Monksdream 1 year ago
CRBU No 1 on the early Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0

Your Recent History

NASDAQ
CRBU
Caribou Biosciences
BIT
NSCIT2919115
Rekeep
BIT
P1T300
NLBNPIT1T300 20241220 17
BIT
I06755
Intesa Sanpaolo
BIT
P1YCS9
NLBNPIT1YCS9 20351221 29...
BIT
P1Z1Y0
NLBNPIT1Z1Y0 20991231 21...
BIT
P1YZC4
NLBNPIT1YZC4 20991231 33...
BIT
WPOZ27
Pozzi Milano
BIT
P1UID6
NLBNPIT1UID6 20991231 50...
BIT
P20532
NLBNPIT20532 20241220 650
BIT
NSCIT01400H9
France
BIT
UB8HS4
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved